MDxHealth SA ADR
$ 2.31
5.00%
17 Apr - close price
- Market Cap 113,002,000 USD
- Current Price $ 2.31
- High / Low $ 2.35 / 2.20
- Stock P/E N/A
- Book Value -0.24
- EPS -0.67
- Next Earning Report 2026-05-14
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.06 %
- ROE -24.40 %
- 52 Week High 5.33
- 52 Week Low 1.55
About
MDxHealth SA is an innovative biotechnology company specializing in precision diagnostics that significantly enhance cancer management, with a primary focus on prostate and bladder cancers. Its leading product, ConfirmMDx for Prostate Cancer, has gained recognition for its clinical effectiveness and substantial market traction. As the shift towards personalized medicine accelerates and the demand for targeted cancer therapies grows, MDxHealth is strategically positioned to broaden its portfolio of cutting-edge diagnostic solutions, addressing critical unmet needs in oncology while aiming to improve patient outcomes and drive sustainable growth.
Analyst Target Price
$7.40
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-26 | 2025-11-12 | 2025-08-14 | 2025-05-14 | 2025-02-26 | 2024-11-06 | 2024-08-21 | 2024-05-01 | 2024-03-06 | 2023-11-08 | 2023-08-23 | 2023-05-15 |
| Reported EPS | -0.17 | -0.16 | -0.14 | -0.19 | -0.14 | -0.4 | -0.42 | -0.31 | -0.39 | -0.4 | -0.3 | -0.5 |
| Estimated EPS | -0.1251 | -0.17 | -0.12 | -0.13 | -0.19 | -0.25 | -0.26 | -0.3 | -0.11 | -0.19 | -0.22 | -0.5 |
| Surprise | -0.0449 | 0.01 | -0.02 | -0.06 | 0.05 | -0.15 | -0.16 | -0.01 | -0.28 | -0.21 | -0.08 | 0 |
| Surprise Percentage | -35.8913% | 5.8824% | -16.6667% | -46.1538% | 26.3158% | -60% | -61.5385% | -3.3333% | -254.5455% | -110.5263% | -36.3636% | 0% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-14 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.13 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: MDXH
2026-04-15 23:39:26
This page provides comprehensive access to MDxHealth SA (MDXH) SEC filings, including annual reports (20-F), quarterly reports via interim 6-K filings, and other material events. It details how these documents offer insights into the company's precision diagnostics business and financial health, with AI-powered summaries available to highlight key information. The most recent filing was on August 14, 2025, an interim report confirming preliminary financials.
2026-04-13 19:39:49
MDxHealth's Chief Commercial Officer, John Bellano, has disclosed an initial statement of beneficial ownership detailing multiple share option awards. These grants span from June 2019 to March 2025, with varying exercise prices, expiration dates, and vesting schedules tied to both time-based installments and company performance criteria. The filing indicates that Bellano directly holds these options, which are not current share trades.
2026-04-13 19:39:49
An MDxHealth SA officer, Joseph Sollee, has filed an initial Form 3 detailing his holdings of share options. The filing outlines numerous option grants with varied exercise prices in both euros and U.S. dollars, distinct vesting schedules, some of which are performance-based, and expiration dates extending as far as 2035. This disclosure provides insight into Sollee's extensive equity incentives with MDxHealth.
2026-04-13 19:39:49
This article details an initial statement of beneficial ownership (Form 3) filed by Ron Kalfus, CFO of MDxHealth SA (MDXH). The filing outlines his holdings of share options, with various strike prices in Euros and USD, and expiration dates ranging from 2029 to 2035. These options generally vest in three equal annual installments or upon achieving specific company performance criteria.
2026-04-13 13:39:49
Short interest in MDxHealth SA (NASDAQ:MDXH) rose significantly by 88.5% in March, indicating increased investor skepticism about the company's near-term performance. The number of shares sold short reached 73,632, representing 0.2% of total shares outstanding, with a short interest ratio of 0.3 days based on current trading volume. This surge suggests potential downward pressure on the stock price and highlights the need for close monitoring by analysts.
2026-04-11 02:39:07
Don M. Hardison, a director at MDxHealth SA (MDXH), has reported initial holdings of 40,000 company share options. These options are divided into two grants: 30,000 ordinary shares at an exercise price of $2.62, granted on June 22, 2024, and 10,000 ordinary shares at $2.18, granted on June 27, 2025, both vesting in full at subsequent annual general shareholders' meetings. The filing is an initial statement of beneficial ownership and does not indicate any open-market buying or selling activity.
